Spectrum Pharma to develop Rituximab biosimilar version with Viropro

Rituximab is a cancer (antineoplastic) medication which works by interfering with the growth of cancer cells by slowing their growth and spread in the body.

Rituximab is also used in the treatment of non-Hodgkin’s lymphoma.

Rituximab destroys both normal and malignant B cells that have CD20 on their surfaces, and is therefore used to treat diseases which are characterized by having too many B cells, overactive B cells or dysfunctional B cells.

Spectrum Pharma chairman, president and CEO Rajesh Shrotriya said that they are excited at the opportunity to develop their own proprietary biosimilar formulation of Rituximab in anticipation of patent expirations for Rituximab over the coming years.